Multiple sclerosis (MS) represents the prototypic inflammatory autoimmune disorder of the central nervous system and the most common cause of neurological disability in young adults. The mainstays in the immunomodulatory therapy of MS are currently interferon beta and glatiramer acetate, both of which have proven to be clinically and paraclinically effective. Current clinical evidence indicates that treatment should be initiated as early as possible. In this review we summarize available data from clinical studies on clinical efficacy of immunomodulatory drugs for treating patients with multiple sclerosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00415-008-6004-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune response profiling of HERV-W envelope proteins in multiple sclerosis: potential biomarkers for disease progression.
Front Immunol
January 2025
Environmental Factors in Degenerative Diseases Research Group. Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Introduction: The envelope proteins syncytin-1 and pHERV-W from the Human Endogenous Retroviral family 'W' (HERV-W) have been identified as potential risk factors in multiple sclerosis (MS). This study aims to evaluate both humoral and cell-mediated immune response to antigenic peptides derived from these proteins across different clinical forms and inflammatory phases of MS.
Methods: Indirect enzyme-linked immunosorbent assay (ELISA) was employed to measure immunoglobulin G (IgG) responses to syncytin-1 and pHERV-W peptides in MS patients.
Lifetime stressors relate to invisible symptoms of multiple sclerosis.
Explor Neuroprotective Ther
April 2024
School of Nursing, University of Michigan, Ann Arbor, MI 48109, USA.
Aim: Childhood stressors can increase adult stress perception and may accumulate over the lifespan to impact symptoms of multiple sclerosis (MS). Growing evidence links childhood stressors (e.g.
View Article and Find Full Text PDFComparing the effects of smartphone-based and face-to-face education on the quality of life and coping skills among patients with multiple sclerosis: A randomized controlled trial.
J Educ Health Promot
December 2024
Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Background: The plethora of troublesome signs and symptoms of multiple sclerosis (MS) reduces patients' quality of life (QOL) and coping skills. Face-to-face (F2F) education is effective and practical as it allows for more engagement and active learning. The use of mobile health technology to enhance health is now an excellent potential to establish a more efficient health system.
View Article and Find Full Text PDFA plain language summary of a study exploring the experiences of people with relapsing-remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better?
Neurodegener Dis Manag
January 2025
dMerck Healthcare KGaA, Darmstadt, Germany.
Effects of Melatonin Supplementation on Muscle Strength, Manual Dexterity, and Postural Balance in Patients Living with Multiple sclerosis - A Randomized Controlled Trial.
J Diet Suppl
January 2025
LINP2, UFR STAPS, University of Paris Nanterre, Nanterre, France.
Our previous study revealed the benefits of chronic melatonin intake on dynamic postural imbalance and poor walking capacity induced by multiple sclerosis but its impact on muscle weakness and poor manual dexterity related to this disease has not yet been explored. The objective of the current study was to investigate the effectiveness of 12-week melatonin supplementation on motor skills (i.e.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!